M&A Deal Summary

Corza Health Acquires Surgical Specialties

On February 1, 2021, Corza Health acquired medical products company Surgical Specialties from Vivo Capital

Acquisition Highlights
  • This is Corza Health’s 2nd transaction in the Medical Products sector.
  • This is Corza Health’s 1st transaction in the United States.
  • This is Corza Health’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-02-01
Target Surgical Specialties
Sector Medical Products
Buyer(s) Corza Health
Sellers(s) Vivo Capital
Deal Type Add-on Acquisition

Target

Surgical Specialties

Westwood, Massachusetts, United States
Surgical Specialties is a medical device company that develops and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions, and acute injury.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Corza Health

San Diego, California, United States
Category Company
Founded 2019
Sector Healthcare Services
DESCRIPTION

Corza Health makes investments in healthcare companies to help accelerate growth. Corza Health invest into high-caliber teams and provides appropriate relationships, learnings and support to create industry-leading brands, products and services. Corza Health was founded in 2019 and is based in San Diego, California.

DEAL STATS #
Overall 2 of 4
Sector (Medical Products) 2 of 4
Type (Add-on Acquisition) 1 of 3
State (Massachusetts) 1 of 1
Country (United States) 1 of 3
Year (2021) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-16 TachoSil

Osaka, Japan

TachoSil provides surgical patches used for bleeding control.

Buy $564M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-02 Katena

Parsippany, New Jersey, United States

Katena is a provider of precision ophthalmic instruments and therapeutics to physician offices, hospitals, and surgical centers. Katena’s product offering includes precision surgical instruments, single-use devices, and specialty biologics that are sold into over 100 countries through a network of direct salespeople and distributors. Katena was founded in 1975 and is based in Parsippany, New Jersey.

Buy -

Seller(S) 1

SELLER

Vivo Capital

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1996
PE ASSETS 6.4B USD
Size Mega
Type Sector Focused
DESCRIPTION

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.

DEAL STATS #
Overall 10 of 14
Sector (Medical Products) 3 of 4
Type (Add-on Acquisition) 2 of 3
State (Massachusetts) 3 of 3
Country (United States) 9 of 12
Year (2021) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-13 IO Biotech

Copenhagen, Denmark

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech's pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2014 and is based in Copenhagen, Denmark.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-22 Impel NeuroPharma

Seattle, Washington, United States

Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. Impel NeuroPharma was formed in 2008 and is based in Seattle, Washington.

Sell -
Mergr

Product

Company

Legal